ArticleEuropean journal of pediatrics2025
Serum ferritin in children with juvenile idiopathic arthritis: a promising subtype-specific marker of disease activity.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathogenic and genetic landscape of Still's disease across ages, with new insights into age-related IL-18 patterns.Arthritis research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While serum ferritin has been established as a marker of disease activity in adults with rheumatoid arthritis, evidence on its role in children with Juvenile Idiopathic Arthritis (JIA) remains limited-particularly among non-systemic subtypes. We aimed to investigate the potential usefulness of serum ferritin levels as a marker of disease activity across the full spectrum of JIA subtypes in children. We retrospectively evaluated 139 children with JIA classified according to the International League of Association for Rheumatology (ILAR) criteria attending our Rheumatology Clinic. A comprehensive assessment was performed. Patients were classified by ILAR subtypes, and disease activity was assessed using JADAS-10 with standard cut-offs. Increased serum ferritin levels were observed in Still's disease (sJIA) and rheumatoid factor (RF)-positive polyarthritis patients compared to other subtypes (p < 0.0001). The highest serum ferritin levels were demonstrated in sJIA and RF-positive polyarthritis patients with high disease activity (p = 0.003). A positive correlation was found between serum ferritin and JADAS-10 score in the study population (r
conclusionIncreased baseline serum ferritin levels were found in children with sJIA and RF-positive polyarthritis exhibiting high disease activity, compared to those with other JIA subtypes. These preliminary findings suggest serum ferritin may as a valuable marker of disease activity across JIA subtypes in pediatric clinical practice. Further prospective studies are warranted to confirm its usefulness in monitoring disease course and treatment response. WHAT IS KNOWN: • Serum ferritin has been recognized as a marker of disease activity in adult patients with RA. • Evidence on the role of ferritin as disease activity marker in children with JIA remains limited, particularly for non-systemic forms. • Limited data exist on TPHA prevalence. WHAT IS NEW: • Serum ferritin levels are associated with high disease activity in children with sJIA and RF positive polyarthritis. • Serum ferritin may serve as a useful marker of disease activity across JIA subtypes, particularly in sJIA and RF-positive polyarthritis, potentially improving the challenging management of these high-risk patients.
Indexed as
Identifiers
40859064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.